Review
Copyright ©The Author(s) 2022.
World J Hepatol. Jan 27, 2022; 14(1): 62-79
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.62
Figure 1
Figure 1 Modification of hepatic and extrahepatic manifestations of chronic hepatitis C after therapy with direct acting agents. Figure represents the main alterations modified by this treatment, as well as those factors that influence the risk: absence of follow-up, previous fibrosis stage, previous decompensation, ongoing liver injury or liver stiffness after sustained viral response. HCV: Hepatitis C virus; SVR: Sustained virologic response; Kpa: Kilopascals.